Cor Vasa 2026, 68(1):87-99 | DOI: 10.33678/cor.2026.001

(Anticoagulation in Maintenance Dialysis Patients with Atrial fibrillation - Consensus Expert Opinion of the Czech Society of Nephrology and the Czech Society of Cardiology)

Štěpán Havráneka, Ivan Rychlíkb, Kryštof Rücklc, d, Eliška Dvořáčkováe, Pavel Osmančíkf, Petr Peichlg, Alena Paříkováh, Martin Havrdab, Vladimír Tesařd, Petr Ošťádalch
a II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
b Interní klinika, 3. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika
c Fresenius Medical Care - DS, s.r.o., Česká republika
d Klinika nefrologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
e Pracoviště klinické farmacie, Nemocnice Na Františku a Farmakologický ústav, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
f Kardiologická klinika, 3. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika
g Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
h Klinika nefrologie, Institut klinické a experimentální medicíny, Praha, Česká republika
ch Kardiologická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Motol a Homolka, Praha, Česká republika

Atrial fibrillation is a frequent arrhythmia in patients with end-stage renal disease and on maintenance dialysis treatment. In the general population, anticoagulation therapy is indicated in patients with arrhyth- mia to prevent cardioembolic complications. In the case of end-stage kidney disease and hemodialysis, the treatment is challenging due to the lack of data or contraindications of some anticoagulants. Patients with advanced chronic kidney disease and patients on hemodialysis are at high risk not only for ischemic cardioembolic events but also for a higher incidence of bleeding complications. This paper aims to describe the criteria for initiation of anticoagulant therapy and to review the advantages and disadvantages of individual pharmacological and non-pharmacological therapies.

Keywords: Anticoagulation, Atrial fibrillation, End-stage kidney disease, Hemodialysis

Received: January 9, 2026; Accepted: January 10, 2026; Prepublished online: June 2, 2012; Published: March 15, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havránek Š, Rychlík I, Rückl K, Dvořáčková E, Osmančík P, Peichl P, et al.. (Anticoagulation in Maintenance Dialysis Patients with Atrial fibrillation - Consensus Expert Opinion of the Czech Society of Nephrology and the Czech Society of Cardiology). Cor Vasa. 2026;68(1):87-99. doi: 10.33678/cor.2026.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    Attachments

    Download filePriloha_ONLINE_Havranek.pdf

    File size: 53.9 kB

    References

    1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014;129:837-847. Go to original source... Go to PubMed...
    2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation 1998;98:946-952. Go to original source... Go to PubMed...
    3. Koplan BA, Winkelmayer WC, Costea AI, et al. Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis. Kidney Int Rep 2022;7:189-199. Go to original source... Go to PubMed...
    4. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio- -Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314-3414. Go to original source... Go to PubMed...
    5. Harel Z, Sholzberg M, Shah PS, et al. Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD. J Am Soc Nephrol 2014;25:431-442. Go to original source... Go to PubMed...
    6. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018;138:1519-1529. Go to original source... Go to PubMed...
    7. Sood MM, Larkina M, Thumma JR, et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 2013;84:600-608. Go to original source... Go to PubMed...
    8. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl 2013;3:368-371.
    9. Malik J, Valerianova A, Pesickova SS, et al. Heart failure with preserved ejection fraction is the most frequent but commonly overlooked phenotype in patients on chronic hemodialysis. Front Cardiovasc Med 2023;10:1130618. Go to original source... Go to PubMed...
    10. Buiten MS, De Bie MK, Rotmans JI, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 2014;100:685-690. Go to original source... Go to PubMed...
    11. Hu A, Liu S, Montez-Rath ME, et al. Associations of Serum and Dialysate Potassium Concentrations With Incident Atrial Fibrillation in a Cohort Study of Older US Persons Initiating Hemodialysis for Kidney Failure. Kidney Int Rep 2023;8:305-316. Go to original source... Go to PubMed...
    12. Zamberg I, Assouline-Reinmann M, Carrera E, et al. Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2022;37:1289-1301. Go to original source... Go to PubMed...
    13. Hörl MP, Hörl WH. Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis 2002;39:227-244. Go to original source... Go to PubMed...
    14. Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant 2015;30:1162-1169. Go to original source... Go to PubMed...
    15. Lee JG, Lee KB, Jang IM, et al. Low Glomerular Filtration Rate Increases Hemorrhagic Transformation in Acute Ischemic Stroke. Cerebrovasc Dis 2013;35:53-59. Go to original source... Go to PubMed...
    16. Zamberg I, Assouline-Reinmann M, Carrera E, et al. Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2022;37:1289-1301. Go to original source... Go to PubMed...
    17. Sood MM, Larkina M, Thumma JR, et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 2013;84:600-608. Go to original source... Go to PubMed...
    18. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-1106. Go to original source... Go to PubMed...
    19. Madken M, Mallick R, Rhodes E, et al. Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD). Can J Kidney Health Dis 2023;10:20543581231169610. Go to original source... Go to PubMed...
    20. Huang C, Li L, Liu W, et al. Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials. Heart Rhythm 2024;21:2422-2428. Go to original source... Go to PubMed...
    21. Randhawa MS, Vishwanath R, Rai MP, et al. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e202175. Go to original source... Go to PubMed...
    22. Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol 2017;28:2241-2248. Go to original source... Go to PubMed...
    23. Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation 2022;146:1735-1745. Go to original source... Go to PubMed...
    24. Reinecke H, Engelbertz C, Bauersachs R, et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation 2023;147:296-309. Go to original source... Go to PubMed...
    25. Kuno T, Takagi H, Ando T, et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis. J Am Coll Cardiol 2020;75:273-285. Go to original source... Go to PubMed...
    26. De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol 2020;31:186-196. Go to original source... Go to PubMed...
    27. De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021;32:1474-1483. Go to original source... Go to PubMed...
    28. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-759. Go to original source... Go to PubMed...
    29. Cope J, Bushwitz J, An G, et al. Clinical Experience With Prophylactic Fondaparinux in Critically Ill Patients With Moderate to Severe Renal Impairment or Renal Failure Requiring Renal Replacement Therapy. Ann Pharmacother 2015;49:270-277. Go to original source... Go to PubMed...
    30. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. Go to original source... Go to PubMed...
    31. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005;45:473-484. Go to original source... Go to PubMed...
    32. Ibanez B, James S. The 2017 ESC STEMI Guidelines. Eur Heart J 2018;39:79-82. Go to original source...
    33. Tanios BY, Itani HS, Zimmerman DL. Clopidogrel Use in End- -Stage Kidney Disease. Semin Dial 2015;28:276-281. Go to original source... Go to PubMed...
    34. Genovesi S, Porcu L, Rebora P, et al. Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J 2023;16:2683-2692. Go to original source... Go to PubMed...
    35. Gallieni M, Hollenbeck M, Inston N, et al. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrol Dial Transplant 2019;34(Supplement_2):ii1-ii42. Go to original source... Go to PubMed...
    36. Afsar B, Afsar RE, Caliskan Y, Lentine KL. Use of Direct Anticoagulants in Kidney Transplant Recipients: Review of the Current Evidence and Emerging Perspectives. Am J Cardiovasc Drugs 2025;25:135-146. Go to original source... Go to PubMed...
    37. Ruff CT, Patel SM, Giugliano RP, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med 2025;392:361-371. Go to original source... Go to PubMed...
    38. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369:2093-2104. Go to original source... Go to PubMed...
    39. Piccini JP, Patel MR, Steffel J, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2025;392:23-32. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content